View Author
jarid jarid 2 es cells analysis patient tumours mutation target expression stromal tumors wild-type stromal information differentiation mouse promoter wild-type es cells 2-2 study imatinib group survival antibody stromal tumours 0.0 level experiment nkx 2‑2 locus tumor mouse es cells right protein 2-deficient prc 1 figure result -/- prc 2 control –jarid enrichment panel tumour histone polycomb pathology pdgfra publisher signi ficantly macmillan ezh 2 suz 12 nkx 2-2 locus 2× flag –jarid bivalent region lamin prc 2 components progression-free survival cancer oct 4 diagnosis immunohistochemical development binding 1.0 component number chromatin input response desmin 0.5 stomach transcription locus metastatic nature target genes 2.0
2 Most Recent Publications
|
Jarid2 is a PRC2 component in embryonic stem cells required for multi-lineage differentiation and recruitment of PRC1 and RNA Polymerase II to developmental regulators
(Article)
Landeira, D. Sauer, S. Brookes, E. Pombo, A. Fisher, C. Skarnes, W.C. Snoek, T. Bezstarosti, K. Demmers, J.A. Klose, R.J. Casanova, M. Tavares, L. Poot, R. Brockdorff, N. Merkenschlager, M. Dvorkina, M. Mazzarella, L. Jørgensen, H.F. Pereira, C.F. Leleu, M. Piccolo, F.M. Spivakov, M. |
2010-06-01
|
|
Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate
(Article)
Sciot, R. Debiec-Rychter, M. Daugaard, S. Fisher, C. Collin, F. Glabbeke, M.M.B. van Verweij, J. Blay, J-Y. Hoogendoorn, P.C.W. |
2008-09-01
|
